1
|
Li A, Ma T, Wang S, Guo Y, Song Q, Liu H, Yu B, Feng S. Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer. Biomed Pharmacother 2024; 173:116240. [PMID: 38401512 DOI: 10.1016/j.biopha.2024.116240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 01/29/2024] [Accepted: 01/30/2024] [Indexed: 02/26/2024] Open
Abstract
Abnormally high expression of lysine-specific demethylase 1 A (LSD1) and DCN1 plays a vital role in the occurrence, development, and poor prognosis of non-small cell lung cancer (NSCLC). Accumulating evidence has shown that the development of small-molecule inhibitors dually targeting LSD1 and the DCN1-UBC12 interaction probably have therapeutic promise for cancer therapy. This work reported that WS-384 dually targeted LSD1 and DCN1-UBC12 interactions and evaluated its antitumor effects in vitro and in vivo. Specifically, WS-384 inhibited A549 and H1975 cells viability and decreased colony formation and EdU incorporation. WS-384 could also trigger cell cycle arrest, DNA damage, and apoptosis. Moreover, WS-384 significantly decreased tumor weight and volume in A549 xenograft mice. Mechanistically, WS-384 increased the gene and protein level of p21 by suppressing the neddylation of cullin 1 and decreasing H3K4 demethylation at the CDKN1A promoter. The synergetic upregulation of p21 contributed to cell cycle arrest and the proapoptotic effect of WS-384 in NSCLC cells. Taken together, our proof of concept studies demonstrated the therapeutic potential of dual inhibition of LSD1 and the DCN1-UBC12 interaction for the treatment of NSCLC. WS-384 could be used as a lead compound to develop new dual LSD1/DCN1 inhibitors for the treatment of human diseases in which LSD1 and DCN1 are dysregulated.
Collapse
Affiliation(s)
- Anqi Li
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China
| | - Ting Ma
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
| | - Shuai Wang
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China
| | - Yueyang Guo
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China
| | - Qianqian Song
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China
| | - Hongmin Liu
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China.
| | - Bin Yu
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, China.
| | - Siqi Feng
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China.
| |
Collapse
|
2
|
Gao S, Wang K, Xiong K, Xiao S, Wu C, Zhou M, Li L, Yuan G, Jiang L, Xiong Q, Yang L. Unraveling the Nrf2-ARE Signaling Pathway in the DF-1 Chicken Fibroblast Cell Line: Insights into T-2 Toxin-Induced Oxidative Stress Regulation. Toxins (Basel) 2023; 15:627. [PMID: 37999490 PMCID: PMC10674583 DOI: 10.3390/toxins15110627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 10/21/2023] [Accepted: 10/24/2023] [Indexed: 11/25/2023] Open
Abstract
The T-2 toxin (T2) poses a major threat to the health and productivity of animals. The present study aimed to investigate the regulatory mechanism of Nrf2 derived from broilers against T2-induced oxidative damage. DF-1 cells, including those with normal characteristics, as well as those overexpressing or with a knockout of specific components, were exposed to a 24 h treatment of 50 nM T2. The primary objective was to evaluate the indicators associated with oxidative stress and the expression of downstream antioxidant factors regulated by the Nrf2-ARE signaling pathway, at both the mRNA and protein levels. The findings of this study demonstrated a noteworthy relationship between the up-regulation of the Nrf2 protein and a considerable reduction in the oxidative stress levels within DF-1 cells (p < 0.05). Furthermore, this up-regulation was associated with a notable increase in the mRNA and protein levels of antioxidant factors downstream of the Nrf2-ARE signaling pathway (p < 0.05). Conversely, the down-regulation of the Nrf2 protein was linked to a marked elevation in oxidative stress levels in DF-1 cells (p < 0.05). Additionally, this down-regulation resulted in a significant decrease in both the mRNA and protein expression of antioxidant factors (p < 0.05). This experiment lays a theoretical foundation for investigating the detrimental impacts of T2 on broiler chickens. It also establishes a research framework for employing the Nrf2 protein in broiler chicken production and breeding. Moreover, it introduces novel insights for the prospective management of oxidative stress-related ailments in the livestock and poultry industry.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Lingchen Yang
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.G.); (K.W.); (K.X.); (S.X.); (C.W.); (M.Z.); (L.L.); (G.Y.); (L.J.); (Q.X.)
| |
Collapse
|
3
|
Xiao S, Wu Y, Gao S, Zhou M, Liu Z, Xiong Q, Jiang L, Yuan G, Li L, Yang L. Deciphering the Hazardous Effects of AFB1 and T-2 Toxins: Unveiling Toxicity and Oxidative Stress Mechanisms in PK15 Cells and Mouse Kidneys. Toxins (Basel) 2023; 15:503. [PMID: 37624260 PMCID: PMC10467080 DOI: 10.3390/toxins15080503] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 08/04/2023] [Accepted: 08/10/2023] [Indexed: 08/26/2023] Open
Abstract
In China, animal feeds are frequently contaminated with a range of mycotoxins, with Aflatoxin B1 (AFB1) and T-2 toxin (T-2) being two highly toxic mycotoxins. This study investigates the combined nephrotoxicity of AFB1 and T-2 on PK15 cells and murine renal tissues and their related oxidative stress mechanisms. PK15 cells were treated with the respective toxin concentrations for 24 h, and oxidative stress-related indicators were assessed. The results showed that the combination of AFB1 and T-2 led to more severe cellular damage and oxidative stress compared to exposure to the individual toxins (p < 0.05). In the in vivo study, pathological examination revealed that the kidney tissue of mice exposed to the combined toxins showed signs of glomerular atrophy. The contents of oxidative stress-related indicators were significantly increased in the kidney tissue (p < 0.05). These findings suggest that the combined toxins cause significant oxidative damage to mouse kidneys. The study highlights the importance of considering the combined effects of mycotoxins in animal feed, particularly AFB1 and T-2, which can lead to severe nephrotoxicity and oxidative stress in PK15 cells and mouse kidneys. The findings have important implications for animal feed safety and regulatory policy.
Collapse
Affiliation(s)
- Shuai Xiao
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| | - Yingxin Wu
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| | - Suisui Gao
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| | - Mingxia Zhou
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| | - Zhiwei Liu
- Wuhan Animal Disease Control Center, No. 170, Erqi Road, Jiang’an District, Wuhan 430014, China;
| | - Qianbo Xiong
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| | - Lihuang Jiang
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| | - Guoxiang Yuan
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| | - Linfeng Li
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| | - Lingchen Yang
- College of Veterinary Medicine, Hunan Agricultural University, No. 1 Nongda Road, Furong District, Changsha 410128, China; (S.X.); (Y.W.); (S.G.); (M.Z.); (Q.X.); (L.J.); (G.Y.); (L.L.)
| |
Collapse
|
4
|
Kargari Aghmiouni D, Khoee S. Dual-Drug Delivery by Anisotropic and Uniform Hybrid Nanostructures: A Comparative Study of the Function and Substrate-Drug Interaction Properties. Pharmaceutics 2023; 15:pharmaceutics15041214. [PMID: 37111700 PMCID: PMC10142803 DOI: 10.3390/pharmaceutics15041214] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 03/23/2023] [Accepted: 04/02/2023] [Indexed: 04/29/2023] Open
Abstract
By utilizing nanoparticles to upload and interact with several pharmaceuticals in varying methods, the primary obstacles associated with loading two or more medications or cargos with different characteristics may be addressed. Therefore, it is feasible to evaluate the benefits provided by co-delivery systems utilizing nanoparticles by investigating the properties and functions of the commonly used structures, such as multi- or simultaneous-stage controlled release, synergic effect, enhanced targetability, and internalization. However, due to the unique surface or core features of each hybrid design, the eventual drug-carrier interactions, release, and penetration processes may vary. Our review article focused on the drug's loading, binding interactions, release, physiochemical, and surface functionalization features, as well as the varying internalization and cytotoxicity of each structure that may aid in the selection of an appropriate design. This was achieved by comparing the actions of uniform-surfaced hybrid particles (such as core-shell particles) to those of anisotropic, asymmetrical hybrid particles (such as Janus, multicompartment, or patchy particles). Information is provided on the use of homogeneous or heterogeneous particles with specified characteristics for the simultaneous delivery of various cargos, possibly enhancing the efficacy of treatment techniques for illnesses such as cancer.
Collapse
Affiliation(s)
- Delaram Kargari Aghmiouni
- Polymer Laboratory, School of Chemistry, College of Science, University of Tehran, Tehran 14155-6455, Iran
| | - Sepideh Khoee
- Polymer Laboratory, School of Chemistry, College of Science, University of Tehran, Tehran 14155-6455, Iran
| |
Collapse
|
5
|
Yap KM, Sekar M, Seow LJ, Gan SH, Bonam SR, Mat Rani NNI, Lum PT, Subramaniyan V, Wu YS, Fuloria NK, Fuloria S. Mangifera indica (Mango): A Promising Medicinal Plant for Breast Cancer Therapy and Understanding Its Potential Mechanisms of Action. BREAST CANCER-TARGETS AND THERAPY 2021; 13:471-503. [PMID: 34548817 PMCID: PMC8448164 DOI: 10.2147/bctt.s316667] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 07/13/2021] [Indexed: 12/12/2022]
Abstract
Globally, breast cancer is the most common cancer type and is one of the most significant causes of deaths in women. To date, multiple clinical interventions have been applied, including surgical resection, radiotherapy, endocrine therapy, targeted therapy and chemotherapy. However, 1) the lack of therapeutic options for metastatic breast cancer, 2) resistance to drug therapy and 3) the lack of more selective therapy for triple-negative breast cancer are some of the major challenges in tackling breast cancer. Given the safe nature of natural products, numerous studies have focused on their anti-cancer potentials. Mangifera indica, commonly known as mango, represents one of the most extensively investigated natural sources. In this review, we provide a comprehensive overview of M. indica extracts (bark, kernel, leaves, peel and pulp) and phytochemicals (mangiferin, norathyriol, gallotannins, gallic acid, pyrogallol, methyl gallate and quercetin) reported for in vitro and in vivo anti-breast cancer activities and their underlying mechanisms based on relevant literature from several scientific databases, including PubMed, Scopus and Google Scholar till date. Overall, the in vitro findings suggest that M. indica extracts and/or phytochemicals inhibit breast cancer cell growth, proliferation, migration and invasion as well as trigger apoptosis and cell cycle arrest. In vivo results demonstrated that there was a reduction in breast tumor xenograft growth. Several potential mechanisms underlying the anti-breast cancer activities have been reported, which include modulation of oxidative status, receptors, signalling pathways, miRNA expression, enzymes and cell cycle regulators. To further explore this medicinal plant against breast cancer, future research directions are addressed. The outcomes of the review revealed that M. indica extracts and their phytochemicals may have potential benefits in the management of breast cancer in women. However, to validate its utility in the creation of innovative and potent therapeutic agents to treat breast cancer, more dedicated research, especially clinical studies are needed to explore the anti-breast cancer potentials of M. indica extracts and their phytochemicals.
Collapse
Affiliation(s)
- Kah Min Yap
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, 30450, Perak, Malaysia
| | - Mahendran Sekar
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, 30450, Perak, Malaysia
| | - Lay Jing Seow
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, 30450, Perak, Malaysia
| | - Siew Hua Gan
- School of Pharmacy, Monash University Malaysia, Bandar Sunway, 47500, Selangor Darul Ehsan, Malaysia
| | - Srinivasa Reddy Bonam
- Institut National de la Santé et de la Recherche Médicale; Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université de Paris, Paris, France
| | - Nur Najihah Izzati Mat Rani
- Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, 30450, Perak, Malaysia
| | - Pei Teng Lum
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, 30450, Perak, Malaysia
| | | | - Yuan Seng Wu
- Faculty of Medicine, Bioscience and Nursing, MAHSA University, Selangor, 42610, Malaysia
| | | | | |
Collapse
|
6
|
Liu L, Fu Y, Zheng Y, Ma M, Wang C. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2020; 78:153312. [PMID: 32866906 DOI: 10.1016/j.phymed.2020.153312] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Revised: 07/26/2020] [Accepted: 08/24/2020] [Indexed: 06/11/2023]
Abstract
BACKGROUND Curcumin functions as a proteasome inhibitor. However, the molecular mechanisms behind this action need more detailed explanations. PURPOSE This study aimed to investigate the inhibitory effect of curcumin on 20S proteasome activity and to elucidate its exact mechanism in triple-negative breast cancer (TNBC) MDA-MB-231 cells. METHODS Proteasomal peptidase activities were assayed using synthetic fluorogenic peptide substrates. Knockdown or overexpression of microRNA (miRNA or miR) or protein was used to investigate its functional effect on downstream cellular processes. BrdU (5‑bromo‑2'-deoxyuridine) assay was performed to identify cell proliferation. Western blot and quantitative real-time PCR(qRT-PCR) were carried out to determine protein abundance and miRNA expression, respectively. Correlations between protein expressions, miRNA levels, and proteasome activities were analyzed in TNBC tissues. Xenograft tumor model was performed to observe the in vivo effect of curcumin on 20S proteasome activity. RESULTS Curcumin significantly reduced PSMB5 protein levels, accompanied with a reduction in the chymotrypsin-like (CT-l) activity of proteasome 20S core. Loss of PSMB5 markedly inhibited the CT-l activity of 20S proteasome. Furthermore, curcumin treatment significantly elevated miR-142-3p expression. PSMB5 was a direct target of miR-142-3p and its protein levels were negatively regulated by miR-142-3p. Moreover, histone acetyltransferase p300 suppressed miR-142-3p expression. Overexpression of p300 mitigated the promotive effect of curcumin on miR-142-3p expression. The correlations among p300 abundances, miR-142-3p levels, PSMB5 expressions, and the CT-l activities of 20S proteasome were evidenced in TNBC tissues. In addition, loss of p300 and PSMB5 reduced cell proliferation. Inhibition of miR-142-3p significantly attenuated the inhibitory impact of curcumin on cell proliferation. These curcumin-induced changes on p300, miR-142-3p, PSMB5, and 20S proteasome activity were further confirmed in in vivo solid tumor model. CONCLUSION These findings demonstrated that curcumin suppressed p300/miR-142-3p/PSMB5 axis leading to the inhibition of the CT-l activity of 20S proteasome. These results provide a novel and alternative explanation for the inhibitory effect of curcumin on proteasome activity and also raised potential therapeutic targets for TNBC treatment.
Collapse
Affiliation(s)
- Le Liu
- Department of Pathology & Pathophysiology, Wuhan University School of Basic Medical Sciences, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China
| | - Yalin Fu
- Department of Pathology & Pathophysiology, Wuhan University School of Basic Medical Sciences, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China
| | - Yuyang Zheng
- Department of Pathology & Pathophysiology, Wuhan University School of Basic Medical Sciences, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China
| | - Mingke Ma
- Department of Pathology & Pathophysiology, Wuhan University School of Basic Medical Sciences, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China
| | - Changhua Wang
- Department of Pathology & Pathophysiology, Wuhan University School of Basic Medical Sciences, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China.
| |
Collapse
|
7
|
Nam SM, Jeon YJ. Proteostasis In The Endoplasmic Reticulum: Road to Cure. Cancers (Basel) 2019; 11:E1793. [PMID: 31739582 PMCID: PMC6895847 DOI: 10.3390/cancers11111793] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 11/04/2019] [Accepted: 11/12/2019] [Indexed: 12/14/2022] Open
Abstract
The endoplasmic reticulum (ER) is an interconnected organelle that is responsible for the biosynthesis, folding, maturation, stabilization, and trafficking of transmembrane and secretory proteins. Therefore, cells evolve protein quality-control equipment of the ER to ensure protein homeostasis, also termed proteostasis. However, disruption in the folding capacity of the ER caused by a large variety of pathophysiological insults leads to the accumulation of unfolded or misfolded proteins in this organelle, known as ER stress. Upon ER stress, unfolded protein response (UPR) of the ER is activated, integrates ER stress signals, and transduces the integrated signals to relive ER stress, thereby leading to the re-establishment of proteostasis. Intriguingly, severe and persistent ER stress and the subsequently sustained unfolded protein response (UPR) are closely associated with tumor development, angiogenesis, aggressiveness, immunosuppression, and therapeutic response of cancer. Additionally, the UPR interconnects various processes in and around the tumor microenvironment. Therefore, it has begun to be delineated that pharmacologically and genetically manipulating strategies directed to target the UPR of the ER might exhibit positive clinical outcome in cancer. In the present review, we summarize recent advances in our understanding of the UPR of the ER and the UPR of the ER-mitochondria interconnection. We also highlight new insights into how the UPR of the ER in response to pathophysiological perturbations is implicated in the pathogenesis of cancer. We provide the concept to target the UPR of the ER, eventually discussing the potential of therapeutic interventions for targeting the UPR of the ER for cancer treatment.
Collapse
Affiliation(s)
- Su Min Nam
- Department of Biochemistry, Chungnam National University College of Medicine, Daejeon 35015, Korea;
- Department of Medical Science, Chungnam National University College of Medicine, Daejeon 35015, Korea
| | - Young Joo Jeon
- Department of Biochemistry, Chungnam National University College of Medicine, Daejeon 35015, Korea;
- Department of Medical Science, Chungnam National University College of Medicine, Daejeon 35015, Korea
| |
Collapse
|
8
|
El Sayed R, El Jamal L, El Iskandarani S, Kort J, Abdel Salam M, Assi H. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Front Oncol 2019; 9:510. [PMID: 31281796 PMCID: PMC6597942 DOI: 10.3389/fonc.2019.00510] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Accepted: 05/28/2019] [Indexed: 01/30/2023] Open
Abstract
Background: Advanced hormone-receptor positive HER2 negative breast cancer is a common and a very heterogeneous disease. Hormone therapy is the main first line treatment of choice, given alone or in combination with other agents that have shown to improve patient outcomes, Nevertheless, treatment remains generally palliative rather than curative. Sequencing of such treatment remains challenging, especially with resurgence of variable resistance patterns. Multiple attempts have been made to overcome resistance and improve patient survival, yet resistance remains not very well understood and metastatic cancer remains a disease with dismal prognosis. Methods: In this paper, we searched pubmed database as well as local and international meetings for all studies discussing advanced and metastatic hormone-receptor-positive, her2-negative breast cancer, hormonal treatment, resistance to hormonal treatment, mechanism of resistance, and means to overcome such resistance. Conclusion: There does not exist an optimal treatment sequence for hormone-receptor-positive, her2-negative advanced breast cancer. However, after review of literature, a reasonable approach may be starting with tamoxifen, aromatase inhibitors, or fulvestrant in absence of visceral crisis, in addition to ensuring adequate ovarian function suppression in pre/peri-menopausal women. Aromatase inhibitors and fulvestrant seem to be superior. Resistance to such agents is increasing, mostly attributed to genetic and molecular changes. Multiple modalities are addressed to overcome such resistance including use of CKD4/6 inhibitors, mTOR inhibitors and PI3K inhibitors in addition to other agents under study, all with promising results. CDK4/6 inhibitors work best when used in frontline setting. Finally, treatment of breast cancer remains a growing field, and more studies are to be awaited.
Collapse
Affiliation(s)
- Rola El Sayed
- Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, American University of Beirut, Beirut, Lebanon
| | - Lara El Jamal
- School of Medicine, American University of Beirut, Beirut, Lebanon
| | | | - Jeries Kort
- Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, American University of Beirut, Beirut, Lebanon
| | | | - Hazem Assi
- Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, American University of Beirut, Beirut, Lebanon
| |
Collapse
|
9
|
Guo KY, Han L, Li X, Yang AV, Lu J, Guan S, Li H, Yu Y, Zhao Y, Yang J, Zhang H. Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway. Oncotarget 2017; 8:114123-114135. [PMID: 29371974 PMCID: PMC5768391 DOI: 10.18632/oncotarget.23166] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 11/28/2017] [Indexed: 02/06/2023] Open
Abstract
Cervical cancer, the third most commonly occurring cancer, is the second leading cause of cancer related mortality among women. Aberrant ubiquitination and proteasome activity, both human papillomavirus and tumor derived, have been shown to contribute to tumor angiogenesis, proliferation, and invasion in many cancers, including cervical cancer. Thus, small molecule proteasome inhibitors are a potential and strategic treatment option for cervical cancer. In this study, novel proteasome inhibitor delanzomib (CEP-18770) exhibited potent pro-apoptotic and cytotoxic effects on a panel of cervical cancer cell lines by blocking proteasomal activity. Delanzomib also significantly sensitized cervical cancer cells to treatment of doxorubicin (Dox), a traditional chemotherapeutic agent. Furthermore, proteasome inhibition revealed stabilization of p53 and p53 transcriptional targets and induction of p38/JNK phosphorylation. Additionally, delanzomib worked synergistically with Dox to further upregulate p53 and its downstream targets and enhanced Dox-induced p38 phosphorylation. Our study strongly supports the 26S proteasome as a potential therapeutic target in cervical cancer and proteasome inhibition by delanzomib may be a potential treatment strategy for cervical cancer patients.
Collapse
Affiliation(s)
- Kevin Y Guo
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.,Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Lili Han
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.,Department of Gynecology, People's Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, Xinjiang 830001, China
| | - Xinyu Li
- Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Andrew V Yang
- Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jiaxiong Lu
- Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Shan Guan
- Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Hui Li
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Yang Yu
- Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Yanling Zhao
- Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jianhua Yang
- Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Hong Zhang
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.,Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
| |
Collapse
|
10
|
Control of Hedgehog Signalling by the Cilia-Regulated Proteasome. J Dev Biol 2016; 4:jdb4030027. [PMID: 29615591 PMCID: PMC5831775 DOI: 10.3390/jdb4030027] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 08/25/2016] [Accepted: 08/29/2016] [Indexed: 12/31/2022] Open
Abstract
The Hedgehog signalling pathway is evolutionarily highly conserved and essential for embryonic development of invertebrates and vertebrates. Consequently, impaired Hedgehog signalling results in very severe human diseases, ranging from holoprosencephaly to Pallister-Hall syndrome. Due to this great importance for human health, the focus of numerous research groups is placed on the investigation of the detailed mechanisms underlying Hedgehog signalling. Today, it is known that tiny cell protrusions, known as primary cilia, are necessary to mediate Hedgehog signalling in vertebrates. Although the Hedgehog pathway is one of the best studied signalling pathways, many questions remain. One of these questions is: How do primary cilia control Hedgehog signalling in vertebrates? Recently, it was shown that primary cilia regulate a special kind of proteasome which is essential for proper Hedgehog signalling. This review article will cover this novel cilia-proteasome association in embryonic Hedgehog signalling and discuss the possibilities provided by future investigations on this topic.
Collapse
|
11
|
Gerhardt C, Leu T, Lier JM, Rüther U. The cilia-regulated proteasome and its role in the development of ciliopathies and cancer. Cilia 2016; 5:14. [PMID: 27293550 PMCID: PMC4901515 DOI: 10.1186/s13630-016-0035-3] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 02/29/2016] [Indexed: 12/21/2022] Open
Abstract
The primary cilium is an essential structure for the mediation of numerous signaling pathways involved in the coordination and regulation of cellular processes essential for the development and maintenance of health. Consequently, ciliary dysfunction results in severe human diseases called ciliopathies. Since many of the cilia-mediated signaling pathways are oncogenic pathways, cilia are linked to cancer. Recent studies demonstrate the existence of a cilia-regulated proteasome and that this proteasome is involved in cancer development via the progression of oncogenic, cilia-mediated signaling. This review article investigates the association between primary cilia and cancer with particular emphasis on the role of the cilia-regulated proteasome.
Collapse
Affiliation(s)
- Christoph Gerhardt
- Institute for Animal Developmental and Molecular Biology, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany
| | - Tristan Leu
- Institute for Animal Developmental and Molecular Biology, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany
| | - Johanna Maria Lier
- Institute for Animal Developmental and Molecular Biology, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany
| | - Ulrich Rüther
- Institute for Animal Developmental and Molecular Biology, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany
| |
Collapse
|
12
|
O'Brien MA, Moravec RA, Riss TL, Bulleit RF. Homogeneous, bioluminescent proteasome assays. Methods Mol Biol 2015; 1219:95-114. [PMID: 25308265 DOI: 10.1007/978-1-4939-1661-0_9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Protein degradation is mediated predominantly through the ubiquitin-proteasome pathway. The importance of the proteasome in regulating degradation of proteins involved in cell-cycle control, apoptosis, and angiogenesis led to the recognition of the proteasome as a therapeutic target for cancer. The proteasome is also essential for degrading misfolded and aberrant proteins, and impaired proteasome function has been implicated in neurodegerative and cardiovascular diseases. Robust, sensitive assays are essential for monitoring proteasome activity and for developing inhibitors of the proteasome. Peptide-conjugated fluorophores are widely used as substrates for monitoring proteasome activity, but fluorogenic substrates can exhibit significant background and can be problematic for screening because of cellular autofluorescence or interference from fluorescent library compounds. Furthermore, fluorescent proteasome assays require column-purified 20S or 26S proteasome (typically obtained from erythrocytes), or proteasome extracts from whole cells, as their samples. To provide assays more amenable to high-throughput screening, we developed a homogeneous, bioluminescent method that combines peptide-conjugated aminoluciferin substrates and a stabilized luciferase. Using substrates for the chymotrypsin-like, trypsin-like, and caspase-like proteasome activities in combination with a selective membrane permeabilization step, we developed single-step, cell-based assays to measure each of the proteasome catalytic activities. The homogeneous method eliminates the need to prepare individual cell extracts as samples and has adequate sensitivity for 96- and 384-well plates. The simple "add and read" format enables sensitive and rapid proteasome assays ideal for inhibitor screening.
Collapse
Affiliation(s)
- Martha A O'Brien
- Promega Corporation, 2800 Woods Hollow Road, Madison, WI, 53711, USA,
| | | | | | | |
Collapse
|
13
|
Roy SS, Kirma NB, Santhamma B, Tekmal RR, Agyin JK. Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells. Cancer Chemother Pharmacol 2014; 73:1263-71. [PMID: 24728817 DOI: 10.1007/s00280-014-2463-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Accepted: 03/31/2014] [Indexed: 11/28/2022]
Abstract
Proteasome inhibition is associated with substantial antitumor effects in preclinical models of multiple myeloma (MM) as well as in patients. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib (Velcade(®), also called PS-341) in MM patients have shown limited activity when used as a single agent. This underscores the need to find new efficacious and less toxic proteasome inhibitors. Recently, carfilzomib was approved for the treatment of refractory/relapsed MM and several new agents have been introduced into the clinic, including marizomib and MLN9708, and trials investigating these second-generation proteasome inhibitors have demonstrated promising results. We have recently synthesized a novel proteasome inhibitor, BU-32, and tested its growth inhibitory effects in different human MM cells including RPMI8226, MM.1S, MM.1R, and U266. In this study, we evaluate the efficacy of the novel proteasome inhibitor BU-32 (NSC D750499) using an in vitro MM model. BU-32 exhibits strong cytotoxicity in a panel of MM cell lines--RPMI8226, MM1S, MM1R, and U266. In addition, we demonstrate by proteasome inhibition assay that BU-32 potently inhibits the chymotryptic- and caspase-like activities of the 26S proteasome. We further show from Annexin V-FITC binding studies that BU-32, like Bortezomib, induces apoptosis in a panel of MM cell lines but the effect is more pronounced with BU-32-treated cells. Invasion assay with the MM.1S cell line indicates that BU-32 inhibits the invasiveness of myeloma cells. Results from our studies using real-time PCR array analyses show that BU-32 effectively downregulates an array of angiogenesis and inflammatory markers. Our results suggest that BU-32 might be a potential chemotherapeutic agent with promising antitumor activity for the treatment of MM.
Collapse
Affiliation(s)
- Sudipa S Roy
- Department of Biochemistry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA
| | | | | | | | | |
Collapse
|
14
|
Agyin JK, Santhamma B, Roy SS. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma. Bioorg Med Chem Lett 2013; 23:6455-8. [PMID: 24119559 PMCID: PMC3836429 DOI: 10.1016/j.bmcl.2013.09.043] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Revised: 09/10/2013] [Accepted: 09/13/2013] [Indexed: 01/11/2023]
Abstract
Multiple myeloma (MM) is an incurable neoplasm characterized by devastating and progressive bone destruction. Standard chemotherapeutic agents have not been effective at significantly prolonging the survival of MM patients and these agents are typically associated with often severe, dose-limiting side effects. There is great need for methods to target the delivery of novel, effective cytotoxic agents specifically to bone, where myeloma cells reside. We have synthesized and evaluated the effects of the bone-targeted proteasome inhibitors PS-341-BP-1, PS-341-BP-2 and MG-262-BP on cell proliferation using the mouse 5TGM1 and human RPMI 8226 cell lines in vitro. The compounds exhibit strong cytotoxicity on MM cell lines and reduce the number of viable cells in a dose dependent manner.
Collapse
Affiliation(s)
- Joseph K Agyin
- University of Texas Health Science Center at San Antonio, Biochemistry Department, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States; University of Texas Health Science Center at San Antonio, Cellular and Structural Biology Department, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States.
| | | | | |
Collapse
|
15
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 1-- #] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
16
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 and 1880=1880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
17
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 8029-- -] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
18
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 8029-- #] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
19
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 1-- gadu] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
20
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 1-- -] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
21
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 8029-- awyx] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
22
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity. Cancer Res 2013; 73:3029-40. [PMID: 23475934 DOI: 10.1158/0008-5472.can-12-3811] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes.
Collapse
Affiliation(s)
- Xin He
- Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA
| | | | | | | | | | | |
Collapse
|
23
|
Kang NH, Hwang KA, Yi BR, Lee HJ, Jeung EB, Kim SU, Choi KC. Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models. Cancer Gene Ther 2012; 19:412-9. [PMID: 22498724 DOI: 10.1038/cgt.2012.15] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
As human amniotic fluid-derived stem cells (hAFSCs) are capable of multiple lineage differentiation, extensive self-renewal and tumor targeting, they may be valuable for clinical anticancer therapies. In this study, we used hAFSCs as vehicles for targeted delivery of therapeutic suicide genes to breast cancer cells. hAFSCs were engineered to produce AF2.CD-TK cells in order to express two suicide genes encoding bacterial cytosine deaminase (CD) and herpes simplex virus thymidine kinase (HSV-TK) that convert non-toxic prodrugs, 5-fluorocytosine (5-FC) and mono-phosphorylate ganciclovir (GCV-MP), into cytotoxic metabolites, 5-fluorouracil (5-FU) and triphosphate ganciclovir (GCV-TP), respectively. In cell viability test in vitro, AF2.CD-TK cells inhibited the growth of MDA-MB-231 human breast cancer cells in the presence of the 5-FC or GCV prodrugs, or a combination of these two reagents. When the mixture of 5-FC and GCV was treated together, an additive cytotoxic effect was observed in the cell viability. In animal experiments using female BALB/c nude mouse xenografts, which developed by injecting MDA-MB-231 cells, treatment with AF2.CD-TK cells in the presence of 5-FC and GCV significantly reduced tumor volume and weight to the same extent seen in the mice treated with 5-FU. Histopathological and fluorescent staining assays further showed that AF2.CD-TK cells were located exactly at the site of tumor formation. Furthermore, breast tissues treated with AF2.CD-TK cells and two prodrugs maintained their normal structures (for example, the epidermis and reticular layers) while breast tissue structures in 5-FU-treated mice were almost destroyed by the potent cytotoxicity of the drug. Taken together, these results indicate that AF2.CD-TK cells can serve as excellent vehicles in a novel therapeutic cell-based gene-directed prodrug system to selectively target breast malignancies.
Collapse
Affiliation(s)
- N-H Kang
- Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
| | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as a first-line therapy in combination with an alkylating agent and a corticosteroid. Furthermore, bortezomib has also been approved as a second-line therapy for mantle cell lymphoma. In this chapter, the focus is on the current clinical research on bortezomib, its adverse effects, and the resistance of multiple myeloma patients to bortezomib-based therapy. The various applications of bortezomib in different diseases and recent advances in the development of a new generation of inhibitors that target the proteasome or other parts of the ubiquitin-proteasome system are also reviewed.
Collapse
Affiliation(s)
- Boris Cvek
- Department of Cell Biology & Genetics, Palacky University, Olomouc, Czech Republic
| |
Collapse
|
25
|
Proteasome inhibitors: Dozens of molecules and still counting. Biochimie 2010; 92:1530-45. [PMID: 20615448 DOI: 10.1016/j.biochi.2010.06.023] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2010] [Accepted: 06/29/2010] [Indexed: 10/19/2022]
Abstract
The discovery of the proteasome in the late 80's as the core protease of what will be then called the ubiquitin-proteasome system, rapidly followed by the development of specific inhibitors of this enzyme, opened up a new era in biology in the 90's. Indeed, the first proteasome inhibitors were instrumental for understanding that the proteasome is a key actor in most, if not all, cellular processes. The recognition of the central role of this complex in intracellular proteolysis in turn fuelled an intense quest for novel compounds with both increased selectivity towards the proteasome and better bioavailability that could be used in fundamental research or in the clinic. To date, a plethora of molecules that target the proteasome have been identified or designed. The success of the proteasome inhibitor bortezomib (Velcade(®)) as a new drug for the treatment of Multiple Myeloma, and the ongoing clinical trials to evaluate the effect of several other proteasome inhibitors in various human pathologies, illustrate the interest for human health of these compounds.
Collapse
|
26
|
Wang G, Yang ZQ, Zhang K. Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res 2010; 2:65-74. [PMID: 20182583 PMCID: PMC2826823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2009] [Accepted: 12/12/2009] [Indexed: 05/28/2023]
Abstract
In eukaryotic cells, the endoplasmic reticulum (ER) is an organelle that is responsible for protein folding and assembly, lipid and sterol biosynthesis, and free calcium storage. In the past decade, intensive research effort has been focused on intracellular stress signaling pathways from the ER that lead to transcriptional and translational reprogramming of stressed cells. These signaling pathways, which are collectively termed Unfolded Protein Response (UPR), are critical for the cell to make survival or death decision under ER stress conditions. In recent years, research in the cancer field has revealed that ER stress and the UPR are highly induced in various tumors and are closely associated with cancer cell survival and resistance to anti-cancer treatments. Identifying the UPR components that are activated or suppressed in malignancy and exploring cancer therapeutic potentials by targeting the UPR are hot research spots. In this review, we summarize the recent progress in understating UPR signaling in cancer and its related therapeutic potential.
Collapse
|